Specific Targeting of Lipid Nanoparticles
Achieve targeted extrahepatic delivery using NanoPilot™ technology.
TechnologyContact usOur Mission
Revolutionising drug delivery
At Hone Bio, we are revolutionising lipid nanoparticle drug delivery. Lipid nanoparticles (LNPs) have shown immense potential for delivering therapeutics—most notably mRNA vaccines—but face a fundamental challenge: most LNPs accumulate in the liver, limiting their use for treating diseases elsewhere in the body.
Our NanoPilot technology addresses this head-on, engineering LNPs that target specific cell types with precision whilst actively blocking off-target liver uptake. Learn more about our technology →
About us
Hone Bio is a VC-backed pre-clinical biotech company based in Bristol, United Kingdom, developing LNP targeting technologies for enhanced drug delivery.
We are proudly part of the Science Creates ecosystem.
Connect with us on LinkedIn.
Contact us
We want to hear from you
If you want to learn more about our technology, are interested in licensing, or have any other enquiries, contact us using the form linked below.
Click here to get in touch